We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Self-Expanding Heart Valve Treats Severe Aortic Stenosis

By HospiMedica International staff writers
Posted on 21 Mar 2018
Print article
Image: The Centera THV system (Photo courtesy of Edwards Lifesciences).
Image: The Centera THV system (Photo courtesy of Edwards Lifesciences).
A novel transcatheter heart valve (THV) valve aids treats patients with severe aortic stenosis requiring aortic valve replacement (AVR).

The Edwards Lifesciences (Irvine, CA, USA) Centera THV system is an ultra-low-profile self-expandable valve that consists of three treated bovine pericardial tissue leaflets attached to a nitinol frame and polyethylene terephthalate (PET) fabric. The stent frame is short, and therefore does not have a flared distal section that extends into the ascending aorta, facilitating centering and seating of the valve within the annulus. The shorter frame may also help to improve paravalvular sealing due to minimal protrusion of the valve frame into the left ventricle. Centera is available in 23 mm and 26 mm sizes.

The THV is provided with the valve pre-attached to the delivery system, facilitating rapid placement using a low-profile, 14F motorized delivery system that allows single-operator repositioning and retrieval. A dynamic expansion mechanism (DEM) allows transient sheath compression during valve delivery; immediately after it passes through, the DEM allows the sheath to return to its original low-profile diameter. Buttons control valve loading and deployment, while a handle release button and valve release mechanism permit the final release of the device.

“The Edwards Centera valve demonstrates extremely favorable early clinical safety and performance outcomes in the high surgical risk TAVR population,” said Didier Tchétché, MD, of Clinique Pasteur (Toulouse, France). “In addition to excellent patient outcomes, the valve also offers several unique features and an innovative tissue design, all of which simplify the procedure for clinicians.”

THV, sometimes called transcatheter aortic valve implantation (TAVI), may be an option for people who are considered at intermediate or high risk of complications from surgical aortic valve replacement. It can also be indicated in those who cannot undergo open-heart surgery.

Related Links:
Edwards Lifesciences
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Hydrogen Peroxide Sterilizer
HMA-30

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.